Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine

Cancer Discov. 2018 Nov;8(11):1352-1354. doi: 10.1158/2159-8290.CD-18-1084.

Abstract

The correlative circulating tumor DNA (ctDNA) studies of the PALOMA-3 clinical trial showed that acquired resistance to fulvestrant and palbociclib is associated with clonal evolution and acquired mutations in RB1, PIK3CA, and ESR1, with the latter two related to fulvestrant resistance. These results highlight the potential of ctDNA as a tool to detect mechanisms of resistance and infer the next line of treatment. Cancer Discov; 8(11); 1352-4. ©2018 AACR See related article by O'Leary et al., p. 1390.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Breast Neoplasms*
  • Circulating Tumor DNA*
  • Clonal Evolution
  • Drug Resistance
  • Fulvestrant
  • Humans
  • Mutation
  • Piperazines
  • Precision Medicine
  • Pyridines

Substances

  • Circulating Tumor DNA
  • Piperazines
  • Pyridines
  • Fulvestrant
  • palbociclib